Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287929 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001100 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL17822576 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001106 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3336886 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001104 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3010731 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL15345921 | 0.82 | UGT2B7 (0.33) | LANCL2UGT2B7 | |
| SCHEMBL15345922 | 0.82 | UGT2B7 (0.33) | LANCL2UGT2B7 | |
| SCHEMBL3989029 | 0.81 | HCAR2 (0.39) | HCRTR1HCRTR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3882246-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-01-31 | — | — | US | disclosed |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-09-06 | — | — | US | disclosed |
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-6566538-B1 | Preparation of 5-(aryloxymethyl)-g-butyrolactone derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-6541647-B2 | Active materials; drugs; antiinflammatory agents; antiallergens | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1094805-A4 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6433197-B1 | REACTING ARYLHYDROXY COMPOUND AND AN EPOXY COMPOUND TO FORM AN EPOXY-ARYL ETHER; REACTING EPOXY-ARYL ETHER WITH ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; REDUCING TO PROVIDE HYDROXY-SUBSTITUTED TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-6310221-B1 | PREPARING A 4-FLUOROPHENOXYMETHYL-(HYDROXY)-TETRAHYDROFURAN BY REACTING 4-FLUOROPHENOL AND AN EPOXY COMPOUND; REACTING THE EPOXY-PHENYL ETHER WITH AN ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; AND REDUCING THE LACTONE | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| US-6306895-B1 | PREPARATION OF CYCLIC OXYGEN COMPOUNDS, INCLUDING 2,5-DISUBSTITUTED TETAHYDROFURANS, 2,6-DISUBSTITUTED TETRAHYDROPYRANS, 2,7-DISUBSTITUTED OXEPANES AND 2,8-OXOCANES. THE INVENTION ALSO PROVIDES NEW CYCLIC OXYGEN COMPOUNDS AND | MILLENIUM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1102759-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-1094805-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001381-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001683-A1 | METHODS FOR SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN COMPOUND | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | OXER1, COX6C, MT-CO2 | LANCL2 1614/4885HCRTR1 772/4885HCRTR2 305/4885 |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | MRPL21, MRM1, MT-CO1 | LANCL2 3554/4885HCRTR1 3544/4885HCRTR2 4587/4885 |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | MRPL21, MRM1, MT-CO1 | LANCL2 3554/4885HCRTR1 3544/4885HCRTR2 4587/4885 |
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | LANCL2 2498/4885HCRTR1 17/4885HCRTR2 8/4885 |
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | BPGM, IL1B, WEE1 | LANCL2 495/4885HCRTR1 4091/4885HCRTR2 4358/4885 |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | PYCR1, PSPH, RPSA | LANCL2 2418/4885HCRTR1 1475/4885HCRTR2 2490/4885 |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | LANCL2 2354/4885HCRTR1 38/4885HCRTR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.